** Shares in Humana fall 3.7% while Clover Health Investment gain 4.5% in premarket trade
** CLOV's PPO Medicare Advantage plans earn a 4-star rating for 2025
** Humana is "likely to track in line" with its estimates last week, which pointed to only a quarter of its members remaining enrolled in 2025 for its 4+ rating plans, compared with 94% in 2024, Oppenheimer said in a note
** The U.S. government said on Friday that 62% of people currently enrolled in Medicare Advantage plans that cover prescription drugs are covered by plans rated four or more stars down from 74% last year
** About 40% of plans being offered are four stars or higher, down from 42% in 2024, it added
(Reporting by Paolo Laudani)
((Paolo.laudani@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。